Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peposertib - Merck KGaA

Drug Profile

Peposertib - Merck KGaA

Alternative Names: M-3814; MSC-2490484A; Nedisertib

Latest Information Update: 13 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck KGaA
  • Developer EMD Serono Research & Development Institute; M. D. Anderson Cancer Center; Merck KGaA; National Cancer Institute (USA); Telix Pharmaceuticals; University of Kentucky
  • Class Antineoplastics; Halogenated hydrocarbons; Morpholines; Pyridazines; Quinazolines; Small molecules
  • Mechanism of Action DNA-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Rectal cancer; Small cell lung cancer
  • Phase I Solid tumours
  • Preclinical Neuroblastoma
  • No development reported Cancer; Chronic lymphocytic leukaemia; Glioblastoma; Neuroendocrine tumours

Most Recent Events

  • 05 Apr 2024 Preclinical trials in Neuroblastoma in USA (PO)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Neuroblastoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 28 Feb 2024 No recent reports of development identified for phase-I development in Cancer(In volunteers) in Germany (PO, Suspension)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top